Prescient Therapeutics’ (ASX:PTX) assets selected for COVID-19 antiviral trial
Two of Prescient Therapeutics' (PTX) assets have been handpicked for a COVID-19 antiviral testing program....
Two of Prescient Therapeutics' (PTX) assets have been handpicked for a COVID-19 antiviral testing program....
Prescient Therapeutics Limited (ASX:PTX) has signed a research agreement with the Peter Doherty Institute for Infection and...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has revealed two of its assets have been selected...
PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from...
Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke joined Steve Darling from Proactive...
Capital dedicated by local investors to risky investments that was once largely tied up in...
The company’s goal is to harness OmniCAR’s innate adaptability and control to develop novel cell...
Anti-cancer biotech company Prescient Therapeutics (PTX) has received two key licences to build a new...
ASX listed biotech company Prescient Therapeutics (ASX: PTX) has this week unveiled two significant licence...
Biotech company Prescient Therapeutics (ASX: PTX) emerged from a trading halt this morning to unveil two significant...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.